18.00
0.05 (0.28%)
| Previous Close | 17.95 |
| Open | 17.85 |
| Volume | 399,560 |
| Avg. Volume (3M) | 544,119 |
| Market Cap | 6,568,956,416 |
| Price / Earnings (Forward) | 14.86 |
| Price / Sales | 1.33 |
| Price / Book | 0.950 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2024 |
| Profit Margin | -7.86% |
| Operating Margin (TTM) | 5.43% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 18.80% |
| Total Debt/Equity (MRQ) | 69.49% |
| Current Ratio (MRQ) | 1.57 |
| Operating Cash Flow (TTM) | 225.00 M |
| Levered Free Cash Flow (TTM) | 137.12 M |
| Return on Assets (TTM) | 0.89% |
| Return on Equity (TTM) | -5.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Bausch + Lomb Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.47% |
| % Held by Institutions | 10.91% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Laurion Capital Management Lp | 30 Sep 2024 | 1,033,880 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (Wells Fargo, 44.44%) | Buy |
| Median | 23.00 (27.78%) | |
| Low | 18.00 (B of A Securities, 0.00%) | Sell |
| Average | 22.29 (23.83%) | |
| Total | 4 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 19.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 12 Dec 2024 | 18.00 (0.00%) | Sell | 18.62 |
| HC Wainwright & Co. | 12 Dec 2024 | 23.00 (27.78%) | Buy | 18.62 |
| 31 Oct 2024 | 23.00 (27.78%) | Buy | 20.28 | |
| Citigroup | 11 Dec 2024 | 22.00 (22.22%) | Hold | 18.16 |
| 31 Oct 2024 | 24.00 (33.33%) | Buy | 20.28 | |
| Morgan Stanley | 02 Dec 2024 | 19.00 (5.56%) | Hold | 19.47 |
| Wells Fargo | 31 Oct 2024 | 26.00 (44.44%) | Buy | 20.28 |
| RBC Capital | 22 Oct 2024 | 23.00 (27.78%) | Buy | 20.35 |
| Evercore ISI Group | 15 Oct 2024 | 25.00 (38.89%) | Buy | 20.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jan 2025 | Announcement | Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
| 12 Dec 2024 | Announcement | Bausch + Lomb Responds to Rumors of a Potential Sale |
| 11 Dec 2024 | Announcement | Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities |
| 14 Nov 2024 | Announcement | Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs |
| 30 Oct 2024 | Announcement | Bausch + Lomb Announces Third-Quarter 2024 Results |
| 14 Oct 2024 | Announcement | Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens |
| 09 Oct 2024 | Announcement | Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |